Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways
- 21 December 2022
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 370, 110329
Abstract
No abstract availableKeywords
Funding Information
- Taipei Medical University Shuang Ho Hospital Ministry of Health and Welfare
This publication has 36 references indexed in Scilit:
- Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancerCell Cycle, 2013
- Label-retaining liver cancer cells are relatively resistant to sorafenibGut, 2013
- Image Classification of Human Carcinoma Cells Using Complex Wavelet-Based Covariance DescriptorsPLOS ONE, 2013
- Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinomaMedical Oncology, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- Identification of Antrocin from Antrodia camphorata as a Selective and Novel Class of Small Molecule Inhibitor of Akt/mTOR Signaling in Metastatic Breast Cancer MDA-MB-231 CellsChemical Research in Toxicology, 2010
- The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal PathwaysMolecular Pharmacology, 2010
- SorafenibDrugs, 2009
- Tumour cell survival signalling by the ERK1/2 pathwayCell Death & Differentiation, 2008